While patients with type 2 diabetes have enjoyed a renaissance of therapies to address these residual risk, with SGLT2Is, GLP-1 RAs, and nsMRAs (finerenone), patients with type 1 diabetes have largely been left behind and excluded from these groundbreaking studies of newer therapeutics
(They started at 2 mg and slowly increased the dose.) To treat adults with type 2 diabetes, people received 4 mg, 9 mg, or 12 mg, depending on their needs
Keeping a written log or using a smartphone application can help track application sites
Although uncommon, liraglutide has been shown to cause mild pancreatitis, with elevated serum amylase or lipase levels
Direct-to-patient (DtP) deliveries: The new legislation supports DtP deliveries of investigational medicinal products, a key aspect of DCTs